Condition: Elderly Patients (>65 Years) · Diabetes (DM) · Heart Disease · Sponsor: Chiara Lanzani
The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.
This description comes directly from the study's public registry record.
Chiara Livia Lanzani, professor · 00390226438131 · lanzani.chiara@hsr.it
Federica Guerra, Dr · 00390226438131 · guerra.federica@hsr.it
Always discuss trial participation with your own doctor first.
| San Raffaele Hospital | Milan, Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07119424